The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Evaluating MYC, BCL2 and BCL6 expression to define double-expressor lymphoma
In this video, Anand Jeyasekharan, MD, National University of Singapore, Singapore, highlights the prognostic role of MYC, BCL2 and BCL6 in diffuse large B-cell lymphoma (DLBCL). Dr Jeyasekharan then goes on to discuss a study which found that there is a subpopulation of cells expressing MYC and BCL2 without BCL6 which can be used to better define and risk stratify patients with double-expressor lymphoma (DEL). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
